Randomized Controlled Trial of Botulinum Toxin Versus Laparoscopic Heller Myotomy for Esophageal Achalasia
- 1 March 2004
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 239 (3) , 364-370
- https://doi.org/10.1097/01.sla.0000114217.52941.c5
Abstract
To compare laparoscopic cardia myotomy and fundoplication with botulinum toxin (BoTx) injection in patients with esophageal achalasia. Although myotomy is thought to offer better results, recent studies have reported 80% success rates after 2 BoTx injections a month apart. No randomized controlled trials comparing the 2 treatments have been published so far. Newly diagnosed achalasia patients were randomly assigned to BoTx injection or laparoscopic myotomy. Symptoms were scored; lower esophageal sphincter resting and nadir pressures were measured by manometry; barium swallow was used to assess esophageal diameter pre- and post-treatment. Eight to one hundred units of BoTx were injected twice, a month apart, at the esophagogastric junction. Myotomy included anterior partial (Dor) or Nissen fundoplication. Eighty patients were involved in the study: 40 received BoTx and 40 underwent myotomy. Mortality was nil. One surgical patient bled from the trocar site. Median hospital stay was 6 days for surgery; BoTox patients were treated as day-hospital admissions. All patients completed the follow-up. After 6 months, the results in the 2 groups were comparable, although symptom scores improved more in surgical patients (82% confidence interval [CI] 76–89 vs. 66% CI 57–75, P < 0.05). The drop in lower esophageal sphincter pressure was similar in the 2 groups; the reduction in esophageal diameter was greater after surgery (19% CI 13–26 vs. 5% CI 2–11, P < 0.05). Later on, symptoms recurred in 65% of the BoTx-treated patients and the probability of being symptom-free at 2 years was 87.5% after surgery and 34% after BoTx (P < 0.05). Laparoscopic myotomy is as safe as BoTx treatment and is a 1-shot treatment that cures achalasia in most patients. BoTx should be reserved for patients who are unfit for surgery or as a bridge to more effective therapies, such as surgery or endoscopic dilation.Keywords
This publication has 28 references indexed in Scilit:
- Long-term follow-up of achalasia patients treated with botulinum toxinDigestive and Liver Disease, 2002
- Minimally Invasive Surgery for Esophageal AchalasiaJournal of Laparoendoscopic & Advanced Surgical Techniques, 2001
- A multicentre randomised study of intrasphincteric botulinum toxin in patients with oesophageal achalasiaGut, 2000
- Does previous endoscopic treatment affect the outcome of laparoscopic Heller myotomy?Annales de Chirurgie, 2000
- Esophageal Achalasia: Intrasphincteric Injection of Botulinum Toxin A Versus Balloon DilationEndoscopy, 1999
- Botulinum toxin versus pneumatic dilatation in the treatment of achalasia: a randomised trialGut, 1999
- Intrasphincteric Botulinum Toxin for the Treatment of AchalasiaNew England Journal of Medicine, 1995
- Heller laparoscopic cardiomyotomy with antireflux anterior fundoplication (Dor) in the treatment of esophageal achalasiaSurgical Endoscopy, 1993
- Long-term effect of total fundoplication on the myotomized esophagusThe Annals of Thoracic Surgery, 1992
- Oesophagitis and pH of refluxate: an experimental and clinical studyBritish Journal of Surgery, 1992